

26 February 2024  
EXT/92874/2024

## Vaccine Monitoring Platform (VMP) list of studies

**Table 1. Studies funded by the European Medicines Agency for the Vaccine Monitoring Platform (VMP)**

Topic	Start date	Current status	HMA-EMA Catalogue	Title and description of the study	Countries
Safety	06/04/2021	Completed	<a href="#">49318</a>	<b>Safety monitoring of COVID-19 vaccines in European countries</b> This study is about understanding the side effects of the different COVID-19 vaccines. Vaccinated people report reactions to the vaccine through electronic questionnaires for up to 6 months after their first vaccine dose, contributing to a broader European understanding of the safety of these vaccines.	Belgium, Croatia, France, Germany, Italy, Luxembourg, Netherlands, United Kingdom
Safety	06/04/2021	Completed	<a href="#">47756</a>	<b>Safety monitoring of COVID-19 vaccines in European countries</b> This study is about understanding the side effects of the different COVID-19 vaccines in vulnerable people (pregnant/lactating women, children, immunocompromised, etc.). Vaccinated people report reactions to the vaccine through electronic questionnaires for up to 6 months after their first vaccine dose, contributing to a broader European understanding of the safety of these vaccines.	Ireland, Italy Netherlands, Portugal, Romania Slovakia, Spain, Switzerland
Safety	06/04/2021	Completed	<a href="#">50433</a> <a href="#">Published study</a>	<b>Readiness to investigate vaccine safety concerns</b> The overall aim of this study is to create a network of electronic healthcare data source to be prepare check if the COVID-19 vaccines are safe. Because it is a large network, even very rare side effects can be investigated. If a potential safety issue is signalled by researchers, regulators or clinicians, this network allows to quickly analyse the matter. For example, the network was used to explore the risk of myocarditis and pericarditis, contributing to generate additional results to support regulatory and public health decision making.	Belgium, Italy, Netherlands, Norway, Spain, United Kingdom
Safety	28/09/2021	Completed	<a href="#">46886</a>	<b>Association between COVID-19 vaccines and thromboembolic events</b> This study investigates the risk of rare blood clots in several large healthcare data sources by tracking people who have this problem and checks antibodies, reactions to vaccines, and safety for 12 months.	Spain, Netherlands, Germany, France, United Kingdom, United States

**Official address** Domenico Scarlattilaan 6 • 1083 HS Amsterdam • The Netherlands

**Address for visits and deliveries** Refer to [www.ema.europa.eu/how-to-find-us](http://www.ema.europa.eu/how-to-find-us)

**Send us a question** Go to [www.ema.europa.eu/contact](http://www.ema.europa.eu/contact) **Telephone** +31 (0)88 781 6000

© European Medicines Agency, 2023. Reproduction is authorised provided the source is acknowledged.

An agency of the European Union



Effectiveness	26/01/2022	Completed	<a href="#">48758</a>	<b>Comparative effectiveness of heterologous and homologous primary- and booster SARS-CoV-2 vaccination schedules in the Nordic countries</b> This study uses data from nationwide healthcare registries in Nordic countries to understand how well COVID-19 vaccines protect against mild or severe COVID-19, and how that protection changes over time. It also checks how mixing different vaccine brands impacts their protective effect.	Denmark, Finland, Norway, Sweden
Effectiveness	20/04/2022	Completed	<a href="#">50294</a>	<b>Effectiveness of COVID-19 vaccination in European countries</b> This study is about COVID-19 vaccines. It uses electronic health care data to understand how well COVID-19 vaccines protect against mild or severe COVID-19, and how that protection changes over time.	Italy, Netherlands, Spain, United Kingdom
Safety	03/08/2022	Completed	<a href="#">50201</a>	<b>Association between COVID-19 vaccines and pediatric safety outcomes in children and adolescents aged 5-19 years in the Nordic countries.</b> This study is about COVID-19 vaccines in children. It uses electronic health care data to understand the safety in children and whether there is a link to immune-related conditions.	Denmark, Finland, Norway, Sweden
Safety and effectiveness	06/10/2022	Ongoing	<a href="#">50282</a>	<b>Safety and Effectiveness of MVA-BN vaccination against MPXV infection in at-risk individuals in Germany</b> This study is about Mpox vaccines. It collects data to understand if the vaccine lowers the risk of getting Mpox and how a person's health condition influence that protection.	Germany
Safety and effectiveness	22/11/2022	Completed	<a href="#">105127</a>	<b>Effectiveness and safety of MVA-BN vaccination against Mpox in at-risk individuals in the United States</b> This study is about Mpox vaccines. It uses electronic health care data to understand how effective and safe it is for men who have sex with men and transgender women in the U.S.	United States
Effectiveness	01/08/2023	Completed	<a href="#">106559</a>	<b>Effectiveness of bivalent Covid-19 booster vaccines in the Nordic countries 2023</b> This study is about the adapted (bivalent) COVID-19 vaccines. It uses data from nationwide registries to understand how well the adapted COVID-19 vaccines protect against severe COVID-19 (including death from COVID-19), and how that protection changes over time.	Denmark, Finland, Norway, Sweden
Effectiveness	18/12/2023	Ongoing		<b>Effectiveness of bivalent Covid-19 booster vaccines in the Nordic countries 2024</b> This study is about the adapted (bivalent) COVID-19 vaccines. It uses data from nationwide registries to understand how well the adapted COVID-19 vaccines protect against severe COVID-19 (including death from COVID-19). It also looks at how that protection changes over time, explores the influence of coadministration with the flu vaccine, and analyses protection against the most recent COVID-19 variants.	Denmark, Finland, Sweden
Safety	07/02/2024	Ongoing		<b>A framework for the post-authorisation safety evaluation of vaccines in the EU</b> This project is about vaccines in general. It uses electronic health care data to create a network that can be used to check if vaccines are safe. Because it is a large network, even very rare events can be investigated. If a potential safety issue is signalled by researchers, regulators or clinicians, the data in this network can quickly analyse the matter. It also looks specifically at immunocompromised people.	
Effectiveness	27/07/2023	Ongoing	<a href="#">107616</a>	<b>DARWIN EU® Effectiveness of COVID 19 vaccines on severe COVID 19 and post-acute outcomes of SARS-CoV-2 infection</b> This study is about COVID-19 vaccines. It aims to understand the real-world effectiveness and duration of protection from COVID-19 vaccines in preventing severe outcomes, mortality, and complications.	United Kingdom, Spain, Netherlands

Disease burden	15/09/2023	Ongoing	<a href="#">107880</a>	<p><b>DARWIN EU® Age specific incidence rates of RSV related disease in Europe</b></p> <p>This study is about the respiratory syncytial virus (RSV). It wants to understand how often people get infected with RSV, how often people are hospitalised for RSV, and how often people die from RSV. This information will help to understand vaccine safety and protection.</p>	United Kingdom, Spain, Germany, France, Estonia
Effectiveness	02/10/2023	Ongoing		<p><b>DARWIN EU® Effectiveness of Human Papillomavirus Vaccines (HPV) to prevent cervical cancer in women.</b></p> <p>This study is about HPV vaccines. It wants to understand how effective they are in preventing severe outcomes like cervical cancer and advanced precancerous lesions. It assesses outcomes by vaccine brand, dose, and age group.</p>	

More information on these studies (for example reports and publications) can be found by clicking on the links in the column “HMA-EMA Catalogue”.